<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60542">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02096835</url>
  </required_header>
  <id_info>
    <org_study_id>TEAS-PONV</org_study_id>
    <nct_id>NCT02096835</nct_id>
  </id_info>
  <brief_title>Transcutaneous Electrical Acupoint Stimulation (TEAS) of P6 to Prevent Postoperation Nausea and Vomiting (PONV)</brief_title>
  <acronym>TPPP</acronym>
  <official_title>Transcutaneous Electrical Acupoint P6 Stimulation vs. Tropisetron to Prevent Postoperation Nausea and Vomiting in Gynecological Patients Undergoing Laparoscopic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <authority>China: Science and Technology Commission of Shanghai Municipality</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to access the effect of TEAS of P6 in the prevention of PONV in
      women scheduled for gynecologic laparoscopic surgery with general anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      130 female patients, aged between 18 to 60 yr, who are scheduled for elective gynecological
      laparoscopic surgery requiring general anesthesia, will be randomly allocated by a computer
      generated randomization table to acustimulation group (Group Acu), tropisetron group (Group
      Trp),or dexamethasone group (Group Dxm).

      In Group Acu, a surface electrode will be applied in the induction room to the P6 acupoint
      30 min before induction.An operator will set electric stimulating current at 1mA with
      frequency at 2 Hz, and gradually increased the current intensity to a little below
      discomfort threshold.The stimulation will be maintained until the patient is discharged from
      the post-anesthesia care unit (PACU). In Group Trp and Group Dxm, the same protocol will be
      applied unless silicone covers attached to both electrodes.

      A standardized anesthetic protocol will be followed. After induction, dexamethasone 10mg
      i.v. will be given in all groups.  All patients will receive intravenous lactated Ringer's
      solution based on calculated preoperative deficits, surgical procedure, and estimated
      intraoperative blood loss. Parecoxib 40mg i.v. during surgery and incision infiltration of
      0.5% ropivacaine at the end of surgery will be used for post-operative analgesia. After
      surgery, analgetic therapy will continue with morphine upon patient's request.After
      extubation, patients will be transported to PACU and observed for no less than 30 min.
      Metoclopramide 10mg i.v. will be administered as a rescue therapy to any patient who
      experiences an episode of moderate or severe nausea, an episode of vomiting, and requests
      rescue medication.

      At the start of skin closure, a prefilled syringe which contains 5 ml of a solution will be
      administered intravenously to the patient. It will contain either saline (Group Acu and
      Group Dxm) or tropisetron 5mg (Group Trp).The syringe with the drug will be prepared by a
      study coordinator according to group allocation.

      The patients, the anesthesiologists, and the nursing staff shall be unaware of the group
      assignments.

      An anesthesiologist and an anesthetic nurse, who are trained for the study and blinded to
      the randomization, will collect the data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Incidence of postoperative nausea and vomiting</measure>
    <time_frame>within 24h after operation</time_frame>
    <safety_issue>No</safety_issue>
    <description>the total incidence including nausea, retching and vomiting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of postoperative nausea</measure>
    <time_frame>2h, 6h, 24h, 48h after the operation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of postoperative vomiting</measure>
    <time_frame>2h, 6h, 24h, and 48h after operation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Including retching and vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>2h, 6h, 24h, and 48h after operation</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of participants who experience headache, constipation,prolonged QT, swelling or pain in the stimulation site which are probably related with tropisetron or TEAS.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Dose of postoperative metoclopramide</measure>
    <time_frame>within 48h after operation</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Dose of postoperative morphine</measure>
    <time_frame>within 24h after operaion</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Acustimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcutaneous electrical acupoint stimulation (TEAS) starts 30 min before surgery and lasts until patient leaves the postanesthetic care unit.Dexamethasone 10mg i.v. after induction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tropisetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tropisetron 5mg iv. at the start of skin closure.Sham transcutaneous electrical acupoint stimulation.Dexamethasone 10mg i.v.after induction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham transcutaneous electrical acupoint stimulation. Dexamethasone 10mg i.v.after induction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcutaneous electrical acupoint stimulation</intervention_name>
    <description>A surface electrode will be applied to the P6 acupoint on the dominant upper extremity, located approximately 3cm proximal to the distal wrist crease between the tendons of the flexor carpi radialis and the palmaris longus, and a negative surface electrode placed on the opposing dorsum aspect of the forearm.</description>
    <arm_group_label>Acustimulation</arm_group_label>
    <other_name>TEAS</other_name>
    <other_name>Electrical neuromuscular stimulation device,JNR-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham transcutaneous electrical acupoint stimulation</intervention_name>
    <description>The same TEAS protocol will be applied unless silicone covers will be attached to both electrodes. The device will also be turned on during the procedure.</description>
    <arm_group_label>Tropisetron</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tropisetron</intervention_name>
    <description>will be given at the start of skin closure</description>
    <arm_group_label>Tropisetron</arm_group_label>
    <other_name>Tropisetron Hydrocloride Injection</other_name>
    <other_name>Batch number:131001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>will be given after induction</description>
    <arm_group_label>Acustimulation</arm_group_label>
    <arm_group_label>Tropisetron</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists (ASA) physical status I or II

          -  aged between 18 to 60yr

          -  scheduled for elective gynecological laparoscopic surgery requiring general
             anesthesia

        Exclusion Criteria:

          -  pregnancy or breastfeeding

          -  mental retardation

          -  psychiatric or neurological disease

          -  use of antiemetics, emetogenic drugs, opioids or glucocorticosteroids within 3 days
             prior to surgery

          -  known allergy to tropisetron or dexamethasone

          -  nausea and/or vomiting within 24 hr prior to surgery

          -  implantation of a cardiac pacemaker, cardioverter, or defibrillator

          -  any skin problem at the acupoint stimulation area
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhang, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anesthesiology, North Institute of Huashan Hospital,Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao-Yu Yang, M.D.</last_name>
    <phone>086-021-52889999</phone>
    <phone_ext>7693</phone_ext>
    <email>xiaoyuyangfudan@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun Zhang, M.D., Ph.D.</last_name>
    <phone>086-021-66895404</phone>
    <email>snapzhang@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Anesthesiology, North Institute of Huashan Hospital,Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201907</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiming Wang, M.D.</last_name>
      <phone>086-021-66895999</phone>
    </contact>
    <investigator>
      <last_name>Xiao-Yu Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yan-Hui Chen, College</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zeng-Tao Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dong-Hua He, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Xiao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lei Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>March 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Xiao-Yu Yang</investigator_full_name>
    <investigator_title>MD.</investigator_title>
  </responsible_party>
  <keyword>Postoperative nausea and vomiting</keyword>
  <keyword>Transcutaneous electrical acupoint stimulation</keyword>
  <keyword>Gynecological laparoscopic surgery</keyword>
  <keyword>Tropisetron</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Tropisetron</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
